罗氏PD-L1单抗-话题@MedSci

#罗氏PD-L1单抗#

4篇内容 | 268人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1807301, encodeId=5f99180e30160, content=<a href='/topic/show?id=4013e961103' target=_blank style='color:#2F92EE;'>#罗氏PD-L1单抗#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=36, createdTime=2021-01-11, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807300, encodeId=d2b3180e300f6, content=<a href='/topic/show?id=4013e961103' target=_blank style='color:#2F92EE;'>#罗氏PD-L1单抗#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=37, createdTime=2019-12-25, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807299, encodeId=c546180e29961, content=<a href='/topic/show?id=4013e961103' target=_blank style='color:#2F92EE;'>#罗氏PD-L1单抗#</a>, objectTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, objectType=article, longId=177619, objectId=7d301e761945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d301e761945, replyNumber=0, likeNumber=53, createdTime=2020-01-17, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d301e761945, moduleTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d301e761945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807298, encodeId=f2a9180e298bb, content=<a href='/topic/show?id=4013e961103' target=_blank style='color:#2F92EE;'>#罗氏PD-L1单抗#</a>, objectTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, objectType=article, longId=177126, objectId=a2121e71269e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2121e71269e, replyNumber=0, likeNumber=48, createdTime=2019-12-11, rootId=0, userName=yige2004, userId=66962500501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2121e71269e, moduleTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2121e71269e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

罗氏PD-L1单抗

2020-05-29

yige2004 (审核中...)

前往app查看评论内容

#罗氏PD-L1单抗#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2021-01-11

yige2004 (审核中...)

前往app查看评论内容

#罗氏PD-L1单抗#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-12-25

yige2004 (审核中...)

前往app查看评论内容

#罗氏PD-L1单抗#

加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法

2020-01-17

yige2004 (审核中...)

前往app查看评论内容

#罗氏PD-L1单抗#

罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人

2019-12-11

科室
- - 订阅+
  - 更多科室
工具
服务